The Journal of Biomedical Optics recently featured a special section on Spatial Frequency Domain Imaging (SFDI). Our founder & CTO, David Cuccia, and our VP of R&D, Amaan Mazhar, served as guest editors for the special section. The section includes fourteen articles that covered a number of topics related to the use and development of SFDI. They comprise review articles on algorithms and applications of SFDI, as well as some of the latest advances in instrumentation and computation. The section includes cutting edge work discussing the use of SFDI for wound assessment, intra-operative guidance, and oncological research.
Of particular note is the comprehensive review article about SFDI in 2019 co-authored by David and Amaan. This special section is an important marker of how SFDI continues to grow as a quantitative method used by researchers to assess tissue properties.
Modulim delivers transformative optical solutions that help people live healthier, longer lives. Clarifi, powered by Spatial Frequency Domain Imaging (SFDI) technology, identifies compromised circulation at the point of care through non-contact rapid microvascular assessment of tissue. Clinicians and healthcare systems are empowered by SFDI images to make proactive, data-driven decisions in a multidisciplinary care setting, in order to reduce lower-limb complications caused by diabetes and peripheral arterial disease. Founded by the inventors of SFDI at the University of California Irvine, Modulim is based in Irvine, CA with a team dedicated to delivering powerful healthcare solutions that elevate and standardize health care delivery, while improving patient outcomes. Modulim is backed by Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK.
Clarifi is a registered trademark of Modulated Imaging (dba Modulim).